Click Therapeutic secures US$52 million in Series B funding to expand prescription portfolio

USA – Click Therapeutic, a prescription digital therapeutic company, has bagged US$52 million Series B funding round led by Health Catalyst Capital, Revelation Partners, Sanofi, K2 HealthVentures, Hima Ventures, and RidgetopHealth. Other participants included Health Catalyst Capital, Revelation Partners, Sanofi, K2 HealthVentures, Hima Ventures, and RidgetopHealth. This announcement comes more than a year after the company signed a US$500 million-plus deal with pharmaceutical company Boehringer Ingelheim to jointly commercialize a digital treatment for schizophrenia patients. Click’s pipeline of innovative digital therapeutics covers a wide range of therapeutic areas, including psychiatry…

Read More

Boehringer launches state-of-the-art biopharma production facility in Vienna

GERMANY – German family-owned biopharma major Boehringer Ingelheim has inaugurated a state-of-the-art biologics facility in Vienna, Austria heralding the single-largest investment in the company’s history. The Large-Scale Cell Culture (LSCC) is one of the most advanced in its own league, boasting a high degree of digitalization and automation through smart technologies and artificial intelligence (AI) applications. The facility boasts a total of 48 stainless-steel bioreactors at various scales, boasts a production capacity of 185,000 liters, exceeding its original planned capacity of 150,000 liters. The facility, which increased mammalian large scale…

Read More

Merck, Bayer’s heart failure therapy Verquvo now approved for use across Europe

WORLD – Verquvo, a drug developed for the treatment of symptomatic chronic heart failure has been cleared for use by the European Commission (EC). The approval reflects another important regulatory milestone in the development of the medicine which will provide doctors, health care professionals and patients with an important treatment option to complement currently available heart failure therapies. Merck and Bayer jointly co-developed Verquvo with Merck holding the commercial rights to the heart failure drug in the US and Bayer having exclusive commercial rights globally. The drug relayed successful data…

Read More

Boehringer Ingelheim’s Pradaxa approved by the FDA for oral pediatric use

USA – The Food and Drug Administration (FDA) has approved Boehringer Ingelheim’s Pradaxa as the first oral blood thinning medication suitable for children 12 years and below in the USA. The medication Pradaxa will be available for use for children with venous thromboembolism immediately after treatment with a blood thinner given by injection for at least five days. Venous thromboembolism (VTE) is a disorder that includes deep vein thrombosis and pulmonary embolism with deep vein thrombosis (DVT) occurring when a blood clot forms in a deep vein, usually in the…

Read More